HALO vs. ILMN: Halozyme Therapeutics vs. Illumina Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Illumina (ILMN) at 32.39% also sits in the top quartile.

Both Halozyme Therapeutics (HALO) at 26.93% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Halozyme Therapeutics (HALO) at 59.84% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Halozyme Therapeutics (HALO) at 3.88 and Illumina (ILMN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Only one side’s leverage can be read here: Illumina (ILMN) carries debt-to-equity ratio of 0.74 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Halozyme Therapeutics (HALO) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Halozyme Therapeutics (HALO) at 25.91 and Illumina (ILMN) at 36.68 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Illumina (ILMN) reports 10.30, ranking against industry peers normally.

Valuation Metrics